Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



基石藥業

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2616)

POLL RESULTS OF EXTRAORDINARY GENERAL MEETING HELD ON JANUARY 17, 2024

Reference is made to the notice of extraordinary general meeting (the "EGM Notice") of CStone Pharmaceuticals (the "Company") dated December 29, 2023. The board of directors (the "Board") of the Company is pleased to announce that the resolution (the "Resolution") set out in the EGM Notice was duly passed by the shareholders (the "Shareholders") of the Company as an ordinary resolution by way of poll at the extraordinary general meeting of the Company held on January 17, 2024 (the "EGM"). Capitalised terms contained in the circular dated December 29, 2023 issued by the Company shall have the same meanings when used herein unless otherwise specified.

The poll results in respect of the Resolution are as follows:

Ordinary Resolution		No. of Votes Cast (%)		Total No.
		For	Against	of Votes Cast (%)
1.	To consider and approve the Grant of Options to Dr. Yang under the Post-IPO ESOP to subscribe for an aggregate of 14,000,000 Shares	246,205,900 (81.032177%)	57,631,303 (18.967823%)	303,837,203 (100.000000%)

Notes:

- 1. As more than 50% of the votes were cast in favour of the Resolution numbered 1, the Resolution numbered 1 proposed at the EGM was duly passed as an ordinary resolution of the Company.
- 2. The full text of the Resolution is set out in the EGM Notice.
- 3. Dr. Yang and his associates, directly and indirectly, holding an aggregate of 61,450,756 Shares of the Company, representing approximately 4.79% of the total issued share capital of the Company as at the date of the EGM, abstained from voting on the Resolution proposed at the EGM. The total Shares entitling the Shareholders to attend and vote on the Resolution proposed at the EGM were 1,222,713,243 Shares.

To the best of the knowledge, information and belief of the Board, and having made all reasonable enquiries:

- (i) there were no Shareholders who were entitled to attend the EGM but was required to abstain from voting in favor of the Resolution proposed at the EGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules");
- (ii) save as Dr. Yang and his associates, none of the Shareholders was required under the Listing Rules to abstain from voting on the Resolution proposed at the EGM; and
- (iii) save as disclosed above, there was no restriction on any Shareholders to cast votes on the Resolution proposed at the EGM and none of the Shareholders have stated their intention in the circular of the Company dated December 29, 2023 to vote against or to abstain from voting on the Resolution at the EGM.
- 4. Computershare Hong Kong Investor Services Limited, the Company's Hong Kong share registrar, was appointed as the scrutineer at the EGM for the purpose of vote-taking in respect of the Resolution.
- 5. The following Directors attended the EGM: Dr. Wei Li, Dr. Jianxin Yang, Mr. Kenneth Walton Hitchner III, Mr. Edward Hu, Mr. Ting Yuk Anthony Wu and Mr. Hongbin Sun. Mr. Xianghong Lin and Dr. Paul Herbert Chew were unable to attend the EGM due to other business commitment.

By Order of the Board CStone Pharmaceuticals Dr. Wei Li Chairman

Hong Kong, January 17, 2024

As at the date of this announcement, the Board comprises Dr. Wei Li as Chairman and non-executive director, Dr. Jianxin Yang as executive director, Mr. Kenneth Walton Hitchner III, Mr. Xianghong Lin and Mr. Edward Hu as non-executive directors, and Dr. Paul Herbert Chew, Mr. Ting Yuk Anthony Wu and Mr. Hongbin Sun as independent non-executive directors.